67971-21-5Relevant academic research and scientific papers
Synthesis and antitumor activity of 2,4,5-trisubstituted-pyrrolo2,3-d]-pyrimidine nucleosides
-
, (2008/06/13)
Certain trisubstituted pyrrolopyrimidine nucleosides are prepared from toyocamycin and have shown antitumor activity against L1210 and P388 murine leukemia. The particular compounds of interest are selected from the following structural formula: STR1 where X is haloY is halo; --NH 2 ; --SH, --SR (where R is lower alkyl, benzyl); --OR (where OR is methoxy or alkoxy or where alk is C1-C6); amino (where the amino is --NH 2, -alkyl amino or -dialkyl amino and alkyl is C1-C6); gamma gamma dimethyl allyl amino; benzyl amino; phenyl amino; selenoZ is CN; CXNH 2 where X is 0, S, or Se, NH, NHNH 2, NOH. OR Z is = --CH 2 NH 2, --COR NHRib β-D-ribofuranosylPreferred members of this group of compounds are shown by the following structural formula: STR2 where X is ClY is Cl or NH 2Z is CN, CONH 2, or C NOH--NH 2These compounds are further identified as NSC #145387 (Compound 5) STR3 NSC #177369 (Compound 6) STR4 NSC #182864 (Compound 8) STR5 NSC #180526 (Compound 10) STR6 These compounds at dosages of 13 - 200 mg/kg of body weight administered every other day on the standard six-day schedule showed activity against both L1210 and P388 murine leukemia (Protocol 11, National Institutes of Health, November 11, 1972).
